Letters, Statements and Analysis

Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.














AMCP Submits Letter to Ways and Means Committee on Ways to Address Rising Drug Costs   

AMCP Supports the Reintroduction of S. 340, the CREATES ACT   

AMCP summary: Food and Drug Administration (FDA) Definition of the Term “Biological Product”   


AMCP submits comments to the Office of Civil Rights (OCR) on its Request for Information on Modifying HIPAA Rules to Improve Coordinated Care   


AMCP Summary: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees   


AMCP joins 50 other organizations in support of the reintroduction of the CREATES Act   



AMCP Summary: Advance Notice of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Draft Call Letter   


On January 28, AMCP submitted comments to HHS and ONC on the HHS Draft Strategy on Reducing Regulatory and Administrative Burden to the Use of Health IT and EHRs.   


AMCP Submits Comments to CMS on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses proposed rulemaking   

Content for class "break" Goes Here